Tekla Capital Management LLC lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 62.6% during the third quarter, Holdings Channel reports. The fund owned 117,377 shares of the biotechnology company's stock after purchasing an additional 45,171 shares during the quarter. Tekla Capital Management LLC's holdings in United Therapeutics were worth $24,576,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Assetmark Inc. grew its stake in United Therapeutics by 25.3% in the third quarter. Assetmark Inc. now owns 266,355 shares of the biotechnology company's stock worth $55,769,000 after purchasing an additional 53,855 shares in the last quarter. James Investment Research Inc. grew its stake in United Therapeutics by 202.2% in the third quarter. James Investment Research Inc. now owns 269 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 180 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its stake in United Therapeutics by 64.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 8,312 shares of the biotechnology company's stock worth $1,728,000 after purchasing an additional 3,272 shares in the last quarter. EFG Asset Management North America Corp. grew its stake in United Therapeutics by 6.4% in the third quarter. EFG Asset Management North America Corp. now owns 12,451 shares of the biotechnology company's stock worth $2,607,000 after purchasing an additional 746 shares in the last quarter. Finally, Securian Asset Management Inc. grew its stake in United Therapeutics by 2.4% in the third quarter. Securian Asset Management Inc. now owns 4,230 shares of the biotechnology company's stock worth $886,000 after purchasing an additional 100 shares in the last quarter. 95.63% of the stock is owned by hedge funds and other institutional investors.
Get United Therapeutics alerts:Insider Transactions at United Therapeutics
In other news, CEO Martine A. Rothblatt sold 8,000 shares of the business's stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $264.85, for a total transaction of $2,118,800.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $34,430.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Martine A. Rothblatt sold 8,000 shares of the business's stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $264.85, for a total transaction of $2,118,800.00. Following the sale, the chief executive officer now owns 130 shares of the company's stock, valued at $34,430.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Judy D. Olian sold 1,010 shares of the business's stock in a transaction that occurred on Friday, December 9th. The stock was sold at an average price of $282.00, for a total value of $284,820.00. Following the sale, the director now directly owns 7,655 shares in the company, valued at approximately $2,158,710. The disclosure for this sale can be found here. Over the last three months, insiders sold 183,390 shares of company stock worth $48,335,135. Company insiders own 12.40% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms recently commented on UTHR. Bank of America reiterated an "underperform" rating on shares of United Therapeutics in a research note on Tuesday, September 20th. Wedbush lifted their price target on United Therapeutics from $250.00 to $305.00 in a research note on Thursday, November 3rd. Oppenheimer lifted their price target on United Therapeutics from $325.00 to $375.00 and gave the stock an "outperform" rating in a research note on Thursday, November 3rd. HC Wainwright lifted their target price on United Therapeutics from $255.00 to $300.00 and gave the company a "buy" rating in a research note on Thursday, November 3rd. Finally, Argus lifted their target price on United Therapeutics from $250.00 to $300.00 and gave the company a "buy" rating in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $283.64.United Therapeutics Stock Performance
Shares of NASDAQ UTHR opened at $261.04 on Friday. The company has a current ratio of 9.68, a quick ratio of 9.39 and a debt-to-equity ratio of 0.18. The stock has a 50 day simple moving average of $271.03 and a 200-day simple moving average of $240.39. The company has a market cap of $11.90 billion, a PE ratio of 17.76, a P/E/G ratio of 1.54 and a beta of 0.62. United Therapeutics Co. has a 12-month low of $158.38 and a 12-month high of $283.09.
United Therapeutics (NASDAQ:UTHR – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.57 by $1.34. The business had revenue of $516.00 million during the quarter, compared to the consensus estimate of $492.92 million. United Therapeutics had a return on equity of 16.63% and a net margin of 38.03%. On average, equities research analysts forecast that United Therapeutics Co. will post 16.63 EPS for the current year.
United Therapeutics Profile
(Get Rating)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Get Rating).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.